Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chung Li

Showing results (741-750 of 757) with videos related to

Pageof 76
Sort By:
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor AntagonistIan M Bell, Steven N Gallicchio, Michael R Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2021
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Cancer Research|October 26, 2018
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line PanelAnne Monks, Yingdong Zhao, Curtis Hose, et al.
Journal of the American Chemical Society|July 25, 2024
Manipulating Ferroelectric Polarization and Spin Polarization of 2D CuInP<sub>2</sub>S<sub>6</sub> Crystals for Photocatalytic CO<sub>2</sub> ReductionChun-Hao Chiang, Cheng-Chieh Lin, Yin-Cheng Lin, et al.
Nanotechnology|July 3, 2024
Efficient photoanode with a MoS<sub>2</sub>/TiO<sub>2</sub>/Au nanoparticle heterostructure for ultraviolet-visible photoelectrocatalysisThe-Hung Mai, Huy-Binh Do, Long Duy Pham, et al.
Frontiers in Oncology|June 3, 2025
Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft modelsYvonne A Evrard, Sergio Y Alcoser, Michael Mullendore, et al.
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Clinical Lung Cancer|August 29, 2022
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L StudyMyung J Ahn, Hye R Kim, James C H Yang, et al.
JCO Precision Oncology|April 30, 2021
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II TrialAlice P Chen, Shivaani Kummar, Nancy Moore, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 13, 2010
Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonistChristopher A Salvatore, Eric L Moore, Amy Calamari, et al.
Pageof 76

Showing results (741-750 of 757) with videos related to

Sort By:
Pageof 76
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor AntagonistIan M Bell, Steven N Gallicchio, Michael R Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2021
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Cancer Research|October 26, 2018
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line PanelAnne Monks, Yingdong Zhao, Curtis Hose, et al.
Journal of the American Chemical Society|July 25, 2024
Manipulating Ferroelectric Polarization and Spin Polarization of 2D CuInP<sub>2</sub>S<sub>6</sub> Crystals for Photocatalytic CO<sub>2</sub> ReductionChun-Hao Chiang, Cheng-Chieh Lin, Yin-Cheng Lin, et al.
Nanotechnology|July 3, 2024
Efficient photoanode with a MoS<sub>2</sub>/TiO<sub>2</sub>/Au nanoparticle heterostructure for ultraviolet-visible photoelectrocatalysisThe-Hung Mai, Huy-Binh Do, Long Duy Pham, et al.
Frontiers in Oncology|June 3, 2025
Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft modelsYvonne A Evrard, Sergio Y Alcoser, Michael Mullendore, et al.
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Clinical Lung Cancer|August 29, 2022
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L StudyMyung J Ahn, Hye R Kim, James C H Yang, et al.
JCO Precision Oncology|April 30, 2021
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II TrialAlice P Chen, Shivaani Kummar, Nancy Moore, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 13, 2010
Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonistChristopher A Salvatore, Eric L Moore, Amy Calamari, et al.
Pageof 76